Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CDC25B | P30305 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.52 |
| ▸ | PDE4A | P27815 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831045 | 1.00 | KMT2A (0.69) | KMT2ATP53MEN1HTTHSD17B10 | |
| SCHEMBL19799375 | 0.84 | KMT2A (0.73) | KMT2ATP53MEN1RAB9AKDM4E | |
| SCHEMBL21121187 | 0.83 | HTT (0.68) | KMT2AMEN1HTTHSD17B10RAB9A | |
| SCHEMBL19799373 | 0.81 | KMT2A (0.70) | KMT2ATP53MEN1RAB9AKDM4E | |
| SCHEMBL23493914 | 0.81 | KMT2A (1.00) | KMT2ATP53MEN1RAB9AKDM4E | |
| SCHEMBL31307866 | 0.81 | KMT2A (1.00) | KMT2ATP53MEN1RAB9AKDM4E | |
| SCHEMBL23409200 | 0.81 | KMT2A (0.73) | KMT2ATP53MEN1HSD17B10RAB9A | |
| SCHEMBL21121195 | 0.81 | HTT (0.65) | KMT2AMEN1HTTHSD17B10RAB9A | |
| SCHEMBL26266880 | 0.80 | KMT2A (0.70) | KMT2ATP53MEN1HTTRAB9A | |
| SCHEMBL11438355 | 0.79 | KDM4E (0.54) | KMT2AMEN1HTTHSD17B10CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2023-09-14 | — | — | US | disclosed |
| CN-116744928-A | Quinolines modulating SERCA and their use for treating diseases | 神经元公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20200347038-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | EIGER BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285382-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | KMT2A 4234/4885TP53 3732/4885MEN1 4119/4885 |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | ATP2A1, ATP2A3, ATP2A2 | KMT2A 4359/4885TP53 3254/4885MEN1 4199/4885 |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | KMT2A 4234/4885TP53 3732/4885MEN1 4119/4885 |
| US-20200347038-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | KMT2A 4234/4885TP53 3732/4885MEN1 4119/4885 |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | KMT2A 4234/4885TP53 3732/4885MEN1 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.